LTRN
$2.33
Lantern Pharma Inc.
Intraday
Recent News
Lantern Pharma (LTRN) Advances Oncology AI and Gains Orphan Drug Recognition
Lantern Pharma, Inc. (NASDAQ:LTRN) is one of the best AI penny stocks to buy right now. On January 20, the FDA granted Lantern Pharma, Inc.’s (NASDAQ:LTRN) LP-284 an Orphan Drug Designation (ODD). LP-284 is an investigational small-molecule therapy for treating soft tissue sarcomas. According to Lantern Pharma, the ODD designation applies in the United States […]
Lantern Pharma (NASDAQ:LTRN) Will Have To Spend Its Cash Wisely
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
FDA clears Starlight Therapeutics’ IND for Phase Ib/IIa glioblastoma trial
The trial aims to assess the tolerability, preliminary efficacy, and safety of the combination therapy in individuals with recurrent GBM.
Lantern Pharma concludes patient enrolment for trial of LP-300 in Japan
The trial is designed to assess the safety and efficacy of LP-300 in never-smoker NSCLC patients.
Here's Why We're Watching Lantern Pharma's (NASDAQ:LTRN) Cash Burn Situation
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...